Analyst reports.

This information is provided for information purposes only. The opinions, estimates, forecasts or any analysis do not represent the opinions, forecasts, or any analysis of our Company or management or staff. We do not by its reference imply any concurrence with the independently provided opinions, estimates or forecasts.

Analyst Reports 2019

Analyst Reports 2019
October 28th 2019

Maxim - Runway Through CY20, Upcoming Catalysts ShouldContinue to Drive a Higher Valuation

October 15th 2019

goetzpartners securities - TACTI-mel final data confirm efficacy signals

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

September 26th 2019

goetzpartners securities - Positive interim analysis for TACTI-002

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

September 23rd 2019

Maxim - GSK Initiates New Trial for IMP731-Derived Therapy, Triggers Milestone to Immutep

September 23rd 2019

goetzpartners securities - Unlockgoetzpartners securities - £4M from GSK extend cash runway to YE2020E

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

July 2nd 2019

Edison - AIPAC fully recruited, results due Q120

April 30th 2019

Maxim - Immutep Provides Corporate Update, Data Points Ahead in 2019

April 23rd 2019

goetzpartners securities - Unlocking the value of LAG-3 in autoimmunity

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

April 8th 2019

Edison - Encouraging results for efti and IMP761

March 27th 2019

LifeSci Capital - Immutep Ltd (IMMP) Positive Signals in Pre-Clinical Studies with IMP761

March 8th 2019

Maxim - Checkpoints on the Flipside of Immune Oncology... Autoimmune disease - Immutep’s LAG-3 IMP761 Highlighted at ECCO

March 6th 2019

Maxim - Advancing the Second Merck Collaboration, TACTI-002 Doses First Patient

March 6th 2019

LifeSci Capital - Immutep Ltd (IMMP) Presents Updated Data from Ongoing TACTI-Mel Study

February 28th 2019

Maxim - Half Year Update: Expecting Data Updates from the LAG3Pipeline in 2019

February 5th 2019

goetzpartners securities - 2019 a decisive year rich in news flow

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

February 1st 2019

Maxim - Provides Update- Catalysts Ahead in 2019 in Several Programs around LAG-3